Precision BioSciences (DTIL) Projected to Post Earnings on Tuesday

Key Points

• Q1 2026 earnings are due before the open on Tuesday, May 5 (call at 9:30 AM ET), with analysts projecting EPS of ($0.6550) and revenue of $4.05 million.
• Insider sales occurred on Feb. 18 — CEO Michael Amoroso sold 20,559 shares and CFO John Alexander Kelly sold 8,149 shares (insiders sold 33,633 shares last quarter and now own 2.70% of the stock).
• DTIL opened near $7.28 (52-week range $3.53–$8.82) with a market cap of ~$188 million, and analysts have a consensus Moderate Buy rating with an average price target of $36.33.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Precision BioSciences to post earnings of ($0.6550) per share and revenue of $4.05 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 9:30 AM ET.

Precision BioSciences Stock Up 1.8%

DTIL stock opened at $7.28 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 13.32 and a quick ratio of 13.32. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $8.82. The company has a 50-day moving average of $6.02 and a two-hundred day moving average of $5.37. The stock has a market capitalization of $187.82 million, a price-to-earnings ratio of -1.42 and a beta of 1.31.

Insider Activity

In related news, CEO Michael Amoroso sold 20,559 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total value of $78,946.56. Following the completion of the sale, the chief executive officer owned 243,392 shares in the company, valued at approximately $934,625.28. This trade represents a 7.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO John Alexander Kelly sold 8,149 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total transaction of $31,292.16. Following the completion of the transaction, the chief financial officer directly owned 125,883 shares of the company's stock, valued at $483,390.72. This trade represents a 6.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 33,633 shares of company stock valued at $129,151. 2.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Precision BioSciences in the fourth quarter worth about $149,000. Sphera Funds Management LTD. acquired a new position in Precision BioSciences in the fourth quarter worth about $1,648,000. Quadrature Capital Ltd raised its position in Precision BioSciences by 344.7% in the fourth quarter. Quadrature Capital Ltd now owns 62,129 shares of the company's stock worth $258,000 after purchasing an additional 48,158 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in Precision BioSciences in the fourth quarter worth about $52,000. Finally, Engineers Gate Manager LP acquired a new position in Precision BioSciences in the fourth quarter worth about $43,000. Institutional investors and hedge funds own 37.99% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on DTIL. JonesTrading restated a "buy" rating and set a $30.00 price target on shares of Precision BioSciences in a report on Friday, April 17th. Wall Street Zen upgraded shares of Precision BioSciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $19.00 target price on shares of Precision BioSciences in a research note on Friday, March 13th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $36.33.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company's pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.